Results 11 to 20 of about 216,402 (213)

In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies. [PDF]

open access: yesPLoS ONE, 2011
BackgroundThe rapid and continual viral escape from neutralizing antibodies is well documented in HIV-1 infection. Here we report in vivo emergence of viruses with heightened sensitivity to neutralizing antibodies, sometimes paralleling the development ...
Marlén M I Aasa-Chapman   +7 more
doaj   +2 more sources

Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus [PDF]

open access: yesCell Reports, 2017
Summary: Drug combinations are synergistic when their combined efficacy exceeds the sum of the individual actions, but they rarely include ineffective drugs that become effective only in combination. We identified several “enabling pairs” of neutralizing
Katie A. Howell   +16 more
doaj   +3 more sources

Hepatitis C virus evasion mechanisms from neutralizing antibodies [PDF]

open access: yes, 2011
Hepatitis C virus (HCV) represents a major public health problem, affecting 3% of the world’s population. The majority of infected individuals develop chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma.
Angus, Allan G.N.   +5 more
core   +1 more source

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. [PDF]

open access: yesPLoS Pathogens, 2017
Human cytomegalovirus (HCMV) is an important, ubiquitous pathogen that causes severe clinical disease in immunocompromised individuals, such as organ transplant recipients and infants infected in utero.
Anna Bootz   +8 more
doaj   +1 more source

Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes [PDF]

open access: yes, 2009
Anti-hepatitis C virus (HCV) cross-neutralizing human monoclonal antibodies, directed against conserved epitopes on surface E2 glycoprotein, are central tools for understanding virus-host interplay, and for planning strategies for prevention and ...
Patel, Ah   +39 more
core   +1 more source

Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies [PDF]

open access: yes, 2014
The increased number of outbreaks of H5 and H7 LPAI and HPAI viruses in poultry has major public and animal health implications. The continuous rapid evolution of these subtypes and the emergence of new variants influence the ability to undertake ...
Rafat Rahman (16267478)   +23 more
core   +1 more source

Identification of a conserved neutralizing epitope in Seneca Valley virus VP2 protein: new insight for epitope vaccine designment

open access: yesVirology Journal, 2022
Background Seneca Valley virus (SVV) is a picornavirus that causes vesicular disease in swine. Clinical characteristics of the disease are similar to common viral diseases such as foot-and-mouth disease virus, porcine vesicular disease virus, and ...
Wei Wen   +5 more
doaj   +1 more source

Llama-Derived Single Domain Antibodies to Build Multivalent, Superpotent and Broadened Neutralizing Anti-Viral Molecules [PDF]

open access: yes, 2011
For efficient prevention of viral infections and cross protection, simultaneous targeting of multiple viral epitopes is a powerful strategy. Llama heavy chain antibody fragments (VHH) against the trimeric envelope proteins of Respiratory Syncytial Virus (
Schepens, B   +94 more
core   +1 more source

Neutralizing Antibodies against SARS-CoV2

open access: yesMedical Journal of Dr. D.Y. Patil Vidyapeeth, 2023
Coronavirus disease 2019 (COVID-19) is an illness due to a novel coronavirus which is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Though this virus is recently identified in 2019, it is closely related to other coronaviruses namely SARS-
Prachi Athavale   +4 more
doaj   +1 more source

Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. [PDF]

open access: yesPLoS ONE, 2014
Recent immune correlates analysis from the RV144 vaccine trial has renewed interest in the role of non-neutralizing antibodies in mediating protection from infection.
Anne-Sophie Dugast   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy